Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2708 | Poly(I:C) | 2 | ug/mL | 4 | IL3 | 32.0 | 31 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL3 | 94.0 | 44 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL3 | 85.0 | 45 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL3 | 81.5 | 36 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL3 | 88.0 | 51 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL3 | 73.5 | 50 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL3 | 82.0 | 41 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL3 | 78.0 | 61 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | IL3 | 83.5 | 52 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL3 | 94.0 | 25 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | IL3 | 80.0 | 36 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IL3 | 82.0 | 50 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | IL3 | 74.0 | 33 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IL3 | 52.0 | 35 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IL3 | 53.5 | 40 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IL3 | 41.0 | 54 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IL3 | 47.0 | 41 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IL3 | 53.0 | 48 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IL3 | 47.0 | 47 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | IL3 | 38.0 | 42 | |
RA2159 | TNF-a | 100 | ng/mL | 4 | IL3 | 50.0 | 43 | ||||
N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | IL3 | 45.0 | 45 | |
N2645 | TNF-a | 100 | ng/mL | 4 | IL3 | 52.5 | 38 | ||||
RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | IL3 | 46.0 | 43 | |
RA2708 | TNF-a | 100 | ng/mL | 4 | IL3 | 55.0 | 50 |